Klein B, Levin I, Kfir B, Mishaeli M, Shapira J, Klein T
Oncology Unit, Golda Medical Center, Petah Tiqva, Israel.
Tumour Biol. 1995;16(5):290-6.
The serum levels of soluble interleukin-2 (sIL-2), sIL-2 receptors (sIL-2R), beta 2-microglobulin (beta 2M) and soluble intercellular adhesion molecule-1 (sICAM-1) were measured by the ELISA technique in 129 breast cancer patients and 40 controls. The median serum levels of sIL2-R, beta 2M and sICAM-1 were significantly higher and sIL-2 significantly lower than controls. sIL-2R, sICAM-1 and beta 2M levels were significantly higher in patients with metastatic disease compared to patients on long-term follow-up with no active disease. Initial study measurements of these markers could not identify patients at high risk for relapse. These findings suggest that the sIL-2R level is indicative of metastatic disease and together with other parameters of immune activation may be of help in monitoring disease activity in breast cancer patients.
采用酶联免疫吸附测定（ELISA）技术，对129例乳腺癌患者和40例对照者检测了血清可溶性白细胞介素-2（sIL-2）、可溶性白细胞介素-2受体（sIL-2R）、β2-微球蛋白（β2M）和可溶性细胞间黏附分子-1（sICAM-1）水平。sIL-2R、β2M和sICAM-1的血清中位数水平显著高于对照组，而sIL-2显著低于对照组。与长期随访无活动性疾病的患者相比，转移性疾病患者的sIL-2R、sICAM-1和β2M水平显著更高。这些标志物的初始研究测量结果无法识别复发高危患者。这些发现表明，sIL-2R水平可指示转移性疾病，与免疫激活的其他参数一起可能有助于监测乳腺癌患者的疾病活动。
